Search results for "RENAL-CELL"

showing 6 items of 6 documents

Alcoholic beverages, obesity, physical activity and other nutritional factors, and cancer risk: A review of the evidence

2016

International audience; Purpose: Prevention is a priority in the fight against cancers, especially nutritional prevention. To update the levels of evidence of relationships between 10 nutritional factors and cancer risk, the scientific literature published from 2006 to 2014 was reviewed by an expert group.Methods: Data from 133 meta-analyses, pooled analyses or intervention trials were examined. Nearly 150 relationships between nutritional factors and cancer at various sites were evaluated.Results: According to the evidence graded as convincing or probable, these factors were divided in two groups. Factors which increase the risk of cancer are alcoholic beverages, overweight and obesity, re…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyGastric cardia adenocarcinomaBreastfeedingReviewOverweightDose-response metaanalysis[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineNeoplasmsPrimary liver-cancerBeta-carotene supplementsBody-mass Index[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyCruciferous vegetables intakeDeveloping lung-cancer030212 general & internal medicineCancer2. Zero hungerProcessed meat consumptionAlcoholic Beverages[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyRenal-cell cancer3. Good healthOncology030220 oncology & carcinogenesisRandomized controlled-trialsRed meatmedicine.symptomAlcoholAlcohol;Beta-carotene supplements;Breastfeeding;Cancer;Diet;Obesity;Physical activity;PreventionBreastfeeding[SDV.CAN]Life Sciences [q-bio]/CancerMotor Activity03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerEnvironmental healthmedicineHumansObesityExerciseCancer preventionbusiness.industryPhysical activityPreventionCancerEvidence-based medicinemedicine.diseaseObesityBeta-carotene supplementationBiotechnologyDietGeriatrics and GerontologybusinessBody mass indexCritical Reviews in Oncology/Hematology
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins

2004

Abstract We recently proposed that Th1 and Th2 cytokines exert opposite effects on the pathogenesis and clinical outcome of organ-specific autoimmunity by altering the expression of genes involved in target cell survival. Because a Th2 response against tumors is associated with poor prognosis, we investigated the ability of IL-4 to protect tumor cells from death receptor- and chemotherapy-induced apoptosis. We found that IL-4 treatment significantly reduced CD95 (Fas/APO-1)- and chemotherapeutic drug-induced apoptosis in prostate, breast, and bladder tumor cell lines. Analysis of antiapoptotic protein expression revealed that IL-4 stimulation resulted in up-regulation of cellular (c) FLIP/F…

MaleINFILTRATING LYMPHOCYTESCell SurvivalImmunologyCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsCARCINOMA-CELLSBiologySIGNALING PATHWAYSDownregulation and upregulationCell Line TumorImmunology and AllergyHumansfas ReceptorNON-HODGKINS-LYMPHOMACANCER PATIENTSReceptorBCL-2 PROTEINInterleukin 4EtoposideIL-4 apoptosis cancer stem cellsSettore MED/04 - Patologia GeneraleCHRONIC LYMPHOCYTIC-LEUKEMIAIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalProstatic NeoplasmsFas receptorRecombinant ProteinsCell biologyUp-RegulationProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureFlipCancer researchT-CELLSCamptothecinFemaleInterleukin-4FLICE-INHIBITORY PROTEINSignal transductionCarrier ProteinsRENAL-CELL
researchProduct

Characterization of a novel population of low-density granulocytes associated with disease severity in HIV-1 infection

2012

The mechanisms resulting in progressive immune dysfunction during the chronic phase of HIV infection are not fully understood. We have previously shown that arginase, an enzyme with potent immunosuppressive properties, is increased in HIV seropositive (HIV+) patients with low CD4(+) T cell counts. Here we show that the cells expressing arginase in peripheral blood mononuclear cells of HIV+ patients are low-density granulocytes (LDGs) and that whereas these cells have a similar morphology to normal-density granulocyte, they are phenotypically different. Importantly, our results reveal that increased frequencies of LDGs correlate with disease severity in HIV+ patients.

Enzyme Metabolismlcsh:MedicineHIV InfectionsBiochemistryACTIVATION0302 clinical medicineImmunophenotypingImmunodeficiency VirusesRENAL-CELL CARCINOMAHIV SeropositivityMedicineSUPPRESSOR-CELLSlcsh:ScienceImmune ResponseCD180303 health scienceseducation.field_of_studyMultidisciplinarymedicine.diagnostic_testT Cellsvirus diseasesMiddle Aged3. Good healthEnzymesSEROPOSITIVE PATIENTSArginasemedicine.anatomical_structurePhenotypeHIV epidemiologyDisease ProgressionMedicineInfectious diseasesScience & Technology - Other TopicsNEUTROPHILResearch ArticleAdultGeneral Science & TechnologyT cellImmune CellsPopulationImmunologyCD18Viral diseasesGranulocytePeripheral blood mononuclear cellMicrobiologyFlow cytometryImmunophenotyping03 medical and health sciencesADHERENCEVirologyMD MultidisciplinaryHumanseducationBiology030304 developmental biologyScience & TechnologyArginasebusiness.industryTetraspanin 30MULTIDISCIPLINARY SCIENCESlcsh:RARGINASE-IHIVVirologyENDOTHELIAL-CELLSAntigens CD63ImmunologyLeukocytes Mononuclearlcsh:Qbusiness030215 immunologyGranulocytes
researchProduct